FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation PlanBusiness Wire • Friday
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)GlobeNewsWire • Friday
Grab These 5 Overlooked Dividend Aristocrats Before Wall Street Catches On24/7 Wall Street • Wednesday
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • Wednesday
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire • Tuesday
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J's Latest Bankruptcy PlanBusiness Wire • Monday
Women Urge Support for $8 Billion J&J Talcum Powder Settlement as July 26th Deadline ApproachesBusiness Wire • Monday
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionPRNewsWire • Monday
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says AnalystBenzinga • 07/18/24
2 Magnificent S&P 500 Dividend Stocks Down 19% and 41% to Buy and Hold ForeverThe Motley Fool • 07/18/24